APLT News and Press, Applied Therapeutics Inc. From 06/23/22

Gainers: F-star Therapeutics (FSTX) +57%. Valneva (VALN) +23%. Nutriband (NTRB) +16%. Rain Therapeutics (RAIN) +15%. uniQure (QURE) +15%. Losers: Applied Therapeutics (APLT) -25%. Mereo BioPharma Group (MREO) -14%. Rigel Pharmaceuticals (RIGL) ...

Applied Therapeutics ( APLT ) -22% on pricing $30M equity offering . Xenon Pharmaceuticals ( XENE ) -13% on pricing $250M equity offering . Clovis Oncology ( CLVS ) -10% Zai Lab ( ZLAB ) -9% on conversion of secondary listing in Ho...

Applied Therapeutics (NASDAQ:APLT) stock sank 24.3% after-hours on Wednesday after the firm has priced its underwritten public offering of 20.0M shares of its common stock, par value $0.0001/share, 10.0M pre-funded warrants to purchase common stock in lieu of common stock to ce...

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...

Applied Therapeutics (NASDAQ:APLT) announced Wednesday its plans to issue shares and accompanying warrants in the underwritten public offering. The clinical stage biopharma company said it intends to use the net proceeds rom this offering for general corporate purposes. SVB Securities is acti...

NEW YORK, June 22, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (NASDAQ: APLT) (the “Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today...

One of the first catalysts to look for when trading penny stocks is news. Company headlines are some of the most prominent and easily accessible pieces of information. In most cases, sporadic moves in the market can be associated with significant updates from companies. Think of it as the f...

The European Medicines Agency (EMA) granted orphan medicinal product designation to Applied Therapeutics' (NASDAQ:APLT) AT-007 (gavorestat) to treat Galactosemia. Galactosemia is a rare, genetic metabolic disorder which affects the body's ability to convert galactose to glucose. ...

NEW YORK, June 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today announced designation of AT-0...

Applied Therapeutics press release (NASDAQ:APLT): Q1 GAAP EPS of -$0.88. Cash and cash equivalents and short-term investments totaled $55.7 million as of March 31, 2022, compared with $80.8 million at December 31, 2021. For further details see: Applied Therapeutics GAAP EPS of -$0.88